Edition:
United Kingdom

Proteon Therapeutics Inc (PRTO.OQ)

PRTO.OQ on NASDAQ Stock Exchange Global Market

1.90USD
3:33pm GMT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.90
Open
$1.90
Day's High
$1.90
Day's Low
$1.90
Volume
15,253
Avg. Vol
10,558
52-wk High
$9.90
52-wk Low
$1.15

Latest Key Developments (Source: Significant Developments)

Proteon Therapeutics Q3 ‍loss per share $1.08​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Proteon Therapeutics Inc :Proteon Therapeutics announces third quarter 2017 financial results.Remain on-track to complete enrollment in Q1 of 2018 in patency-2, co's second phase 3 clinical trial of vonapanitase​.Qtrly ‍loss per share $1.08​.Expects its cash, cash equivalents, available-for-sale investments will be sufficient to fund its operations into Q4 of 2019,.Q3 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S.  Full Article

Proteon Therapeutics announces data from trial of investigational vonapanitase in patients with CKD
Tuesday, 13 Dec 2016 

Proteon Therapeutics Inc : Secondary and tertiary endpoint data and enrollment in second phase 3 ongoing . Trial did not meet primary efficacy endpoint .Announces top-line data from phase 3 patency-1 clinical trial of investigational vonapanitase in patients with CKD.  Full Article

Proteon Therapeutics says expects to initiate 2 planned phase 1 clinical studies evaluating vonapanitase in 2016
Tuesday, 25 Oct 2016 

Proteon Therapeutics Inc : Proteon Therapeutics announces overview of phase 1 clinical program of investigational vonapanitase in peripheral artery disease to be presented at the 28th transcatheter cardiovascular therapeutics (TCT) conference .Proteon Therapeutics Inc- company expects to initiate two planned phase 1 clinical studies evaluating Vonapanitase in 2016.  Full Article

Proteon Therapeutics Qtrly loss per share $0.48
Monday, 8 Aug 2016 

Proteon Therapeutics Inc: Proteon Therapeutics announces second quarter 2016 financial results .Line data from first phase 3 study, patency-1, this december.  Full Article

Proteon Therapeutics qtrly loss per share $0.40
Monday, 9 May 2016 

Proteon Therapeutics Inc : Qtrly loss per share $0.40 . Q1 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S .Proteon therapeutics announces first quarter 2016 financial results.  Full Article

BRIEF-Proteon Therapeutics Q3 ‍loss per share $1.08​

* Proteon Therapeutics announces third quarter 2017 financial results